US 11,981,659 B2
Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
Sang Ho Oh, Gyeonggi-do (KR); Jong Gyun Kim, Gyeonggi-do (KR); Se-Woong Oh, Gyeonggi-do (KR); Tae Dong Han, Gyeonggi-do (KR); Soo Yong Chung, Gyeonggi-do (KR); Seong Ran Lee, Gyeonggi-do (KR); Kyeong Bae Kim, Seoul (KR); Young Sung Lee, Seoul (KR); Woo Seob Shin, Gyeonggi-do (KR); Hyun Ju, Gyeonggi-do (KR); Jeong Ki Kang, Gyeonggi-do (KR); Su Min Park, Chungcheongbuk-do (KR); and Dong Kyun Kim, Gyeonggi-do (KR)
Assigned to Yuhan Corporation, Seoul (KR)
Filed by Yuhan Corporation, Seoul (KR)
Filed on Mar. 17, 2022, as Appl. No. 17/697,655.
Application 17/697,655 is a continuation of application No. 16/605,944, granted, now 11,453,656, previously published as PCT/KR2018/004473, filed on Apr. 18, 2018.
Claims priority of application No. 10-2017-0051687 (KR), filed on Apr. 21, 2017.
Prior Publication US 2023/0021395 A1, Jan. 26, 2023
Int. Cl. C07D 403/04 (2006.01); C07C 303/22 (2006.01); C07C 309/04 (2006.01)
CPC C07D 403/04 (2013.01) [C07C 303/22 (2013.01); C07C 309/04 (2013.01); C07B 2200/13 (2013.01)] 17 Claims
 
1. A method of treating a protein kinase-mediated disorder, which comprises the step of administering to a subject a mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, as represented by the following Formula 1:

OG Complex Work Unit Chemistry
which is in a crystalline form (I) that has diffraction peaks in a PXRD (powder X-ray diffraction) graph present at 2θ (theta) angles of 5.614±0.2, 17.143±0.2, and 21.585±0.2 degrees.